Partner Alexander Chae is quoted in an article published in Of Counsel’s Diversity Report section, “Firms Make Strides but Still Not Achieving Sufficient Progress.” In the article, Chae covers various topics that impact law firm diversity, such as minority retention, comparisons to corporate America and the tendency of millennials to change jobs.
He says that diversity is essential because it creates a more holistic workforce, benefitting both law firms and their clients.
“The people who are purchasing our services are not just white males,” said Chae. “They’re comforted to know that we have people who may come from similar backgrounds, and have similar experiences and perspectives. It’s an absolute necessity to have that. It’s not an option: It’s a must.”
He says that diversity is essential because it creates a more holistic workforce, benefitting both law firms and their clients.
“The people who are purchasing our services are not just white males,” said Chae. “They’re comforted to know that we have people who may come from similar backgrounds, and have similar experiences and perspectives. It’s an absolute necessity to have that. It’s not an option: It’s a must.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”